MX2009010451A - Peptidos con capacidad para unirse a la interleuquina 10 (il-10). - Google Patents

Peptidos con capacidad para unirse a la interleuquina 10 (il-10).

Info

Publication number
MX2009010451A
MX2009010451A MX2009010451A MX2009010451A MX2009010451A MX 2009010451 A MX2009010451 A MX 2009010451A MX 2009010451 A MX2009010451 A MX 2009010451A MX 2009010451 A MX2009010451 A MX 2009010451A MX 2009010451 A MX2009010451 A MX 2009010451A
Authority
MX
Mexico
Prior art keywords
interleukine
peptides
binding
capacity
expression
Prior art date
Application number
MX2009010451A
Other languages
English (en)
Inventor
Francisco Borras Cuesta
Jesus Prieto Valtuena
Javier Dotor De Las Herrerias
Pablo Sarobe Ugarriza
Lorea Manterola Careaga
Ines Noelia Casares Lagar
Nancy Diaz-Valdes Farray
Juan Jose Lasarte Sagastibelza
Original Assignee
Proyecto Biomedicina Cima Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Biomedicina Cima Sl filed Critical Proyecto Biomedicina Cima Sl
Publication of MX2009010451A publication Critical patent/MX2009010451A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8291—Hormone-influenced development
    • C12N15/8295—Cytokinins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)

Abstract

Se describen péptidos que tienen la capacidad de unirse a la interleuquina 10 (IL-10) y su empleo en el tratamiento de condiciones clínicas o alteraciones patológicas asociadas con expresión de IL-10, en particular, con una expresión elevada de IL-10, por ejemplo, enfermedades infecciosas, tumores, cánceres y situaciones de daño agudo.
MX2009010451A 2007-03-27 2008-03-27 Peptidos con capacidad para unirse a la interleuquina 10 (il-10). MX2009010451A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200700806A ES2304315B1 (es) 2007-03-27 2007-03-27 Peptidos con capacidad para unirse a la interleuquina 10 (il-10).
PCT/ES2008/000181 WO2008116956A2 (es) 2007-03-27 2008-03-27 Péptidos con capacidad para unirse a la interleuquina 10 (il-10)

Publications (1)

Publication Number Publication Date
MX2009010451A true MX2009010451A (es) 2009-12-14

Family

ID=39744788

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010451A MX2009010451A (es) 2007-03-27 2008-03-27 Peptidos con capacidad para unirse a la interleuquina 10 (il-10).

Country Status (11)

Country Link
US (2) US8148334B2 (es)
EP (1) EP2157098A2 (es)
JP (1) JP2010522551A (es)
CN (1) CN101679488A (es)
AU (1) AU2008231660A1 (es)
BR (1) BRPI0809373A2 (es)
CA (1) CA2682021A1 (es)
ES (1) ES2304315B1 (es)
MX (1) MX2009010451A (es)
RU (1) RU2009139651A (es)
WO (1) WO2008116956A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014227338A (ja) * 2013-05-17 2014-12-08 キヤノン株式会社 インドシアニングリーン含有粒子およびその製造方法
CN104231054A (zh) * 2014-09-01 2014-12-24 王跃建 Il-10多肽抑制剂
US10512673B2 (en) * 2015-01-07 2019-12-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of peptide-based inhibitors of the stat3-IL10 pathway for treating bacterial infection and granulomatous disease
CN108030916A (zh) * 2015-07-03 2018-05-15 刘永庆 防治肿瘤和/或慢性结核病的Th2免疫反应抑制剂及其应用
BR102019007044A2 (pt) * 2019-04-05 2021-12-28 Universidade Federal de Uberlândia Peptídeos sintéticos com afinidade ao receptor de interleucina-10, composição farmacêutica e uso dos mesmos como imunomuduladores no tratamento de doenças autoimunes, inflamatórias ou alérgicas
CN114931547B (zh) * 2022-05-16 2023-04-28 四川大学华西医院 治疗牙槽骨损伤的多肽水凝胶及其制备方法和用途
CN117362396A (zh) * 2022-06-23 2024-01-09 浙江大学 一种特异性亲和白介素-10的亲和多肽及其用途
CN117534732A (zh) * 2023-11-03 2024-02-09 湖南中晟全肽生化有限公司 一种抑制il-12与其受体结合的多肽及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08151396A (ja) * 1994-11-28 1996-06-11 Teijin Ltd Ｈｌａ結合性オリゴペプチド及びそれを含有する免疫調節剤
FR2729960A1 (fr) 1995-01-30 1996-08-02 Bio Merieux Polypeptides mimotopes de toxoplasma gondii et applications
AU2531397A (en) * 1996-03-21 1997-10-10 President And Fellows Of Harvard College Enantiomeric screening process, and compositions therefor
JPH10237098A (ja) * 1997-02-26 1998-09-08 Immuno Japan:Kk 糖脂質糖鎖レプリカペプチド
WO2006031727A2 (en) * 2004-09-13 2006-03-23 President And Fellows Of Harvard College Peptides for treatment of autoimmune diseases
EP1901769A2 (en) * 2005-05-02 2008-03-26 Avigen, Inc. Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease

Also Published As

Publication number Publication date
AU2008231660A1 (en) 2008-10-02
CN101679488A (zh) 2010-03-24
WO2008116956A3 (es) 2008-12-18
CA2682021A1 (en) 2008-10-02
ES2304315B1 (es) 2009-07-28
ES2304315A1 (es) 2008-10-01
WO2008116956A2 (es) 2008-10-02
JP2010522551A (ja) 2010-07-08
US8148334B2 (en) 2012-04-03
US20100168015A1 (en) 2010-07-01
US20130064790A1 (en) 2013-03-14
RU2009139651A (ru) 2011-05-10
BRPI0809373A2 (pt) 2014-11-11
EP2157098A2 (en) 2010-02-24

Similar Documents

Publication Publication Date Title
MX2009010451A (es) Peptidos con capacidad para unirse a la interleuquina 10 (il-10).
IL273422A (en) Methods and systems for extracorporeal organ treatment
WO2007002662A3 (en) Anti-inflammatory, radioprotective, and longevity enhancing capabilities of cerium oxide nanoparticles
UA105210C2 (ru) Противораковая вакцина и ее применение
WO2018033254A3 (en) Rna for cancer therapy
HK1135431A1 (en) Therapeutic applications of activation of human antigen-presenting cells through dectin-1
MXPA05008128A (es) Peptidos derivados de survivina y uso de los mismos.
JO3076B1 (ar) نظم العلاج المناعي المعتمد على حالة apoe
IL190796A0 (en) Compositions and their uses for gene therapy of bone conditions
RS20160203A1 (sr) Tretman sa anti-vegf antitelima
EP2597464A3 (en) Metabolomic profiling of prostate cancer
EP1937845A4 (en) MICRO-RNA-BASED METHOD AND COMPOSITIONS FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF BREAST CANCER
ES2422739T3 (es) Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB
IL184617A0 (en) Dr5 antibodies and uses thereof
EP1814909A4 (en) USE OF AIMP2DX2 FOR THE DIAGNOSIS AND TREATMENT OF CANCER
TR201821029T4 (tr) Geliştirilmiş antı-IL-23p19 antikorları.
IL201479A (en) Use of tapentadol for the preparation of pain medication
EP1940456A4 (en) WWOX GENE, VECTORS COMPRISING THE SAME, AND USES THEREOF IN THE TREATMENT OF CANCER
MX2009008918A (es) Activacion de celulas que presentan antigeno humano a traves de clec-6.
IN2015DN01788A (es)
HK1116186A1 (en) Azaxanthones and use thereof for treating tumors
EP1978983A4 (en) EXTRACT OF DIOSCOREA SP. AND ITS MEDICAL USES
NZ584606A (en) An ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
WO2006045874A3 (es) Empleo del gen slug, o de sus productos de replicación, transcripción o expresión, en la identificación, diagnóstico, prevención o tratamiento de la diseminación del cáncer y/o desarrollo de metástasis
WO2007027344A3 (en) Compounds and methods for the treatment of cancer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal